ORIC Pharmaceuticals (ORIC) Expected to Announce Quarterly Earnings on Monday

ORIC Pharmaceuticals (NASDAQ:ORIC) is projected to announce its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.01. On average, analysts expect ORIC Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ORIC Pharmaceuticals Stock Up 1.9 %

Shares of NASDAQ:ORIC opened at $8.00 on Friday. ORIC Pharmaceuticals has a 52 week low of $6.33 and a 52 week high of $16.37. The stock has a market capitalization of $568.22 million, a P/E ratio of -4.40 and a beta of 1.25. The firm has a fifty day simple moving average of $9.22 and a two-hundred day simple moving average of $9.39.

Insider Activity at ORIC Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 8,851 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,286.28. Following the completion of the sale, the chief financial officer now owns 106,764 shares in the company, valued at approximately $884,005.92. The trade was a 7.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Pratik S. Multani sold 8,850 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $73,278.00. Following the completion of the sale, the insider now owns 46,765 shares of the company’s stock, valued at approximately $387,214.20. This represents a 15.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,361 shares of company stock worth $350,749 in the last 90 days. 5.55% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have commented on ORIC shares. Wedbush reissued an “outperform” rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Monday, January 13th. JPMorgan Chase & Co. lifted their price objective on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Friday, February 21st. Finally, Guggenheim reaffirmed a “buy” rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $18.86.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.